AKR1B1 and hepatocellular carcinoma: These results suggest that AKR1B1 is upregulated during drug therapy, thereby mediating cellular survival under therapeutic stress conditions, indicating its potential utility as a biomarker for predicting therapeutic resistance in HCC patients.